- Mepolizumab: Uses, Dosage, Side Effects, Warnings - Drugs. com
Mepolizumab is used to treat several eosinophil-related conditions including Hypereosinophilic Syndrome (HES), Eosinophilic Granulomatosis with Polyangiitis (EGPA), severe asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP)
- Mepolizumab - Wikipedia
Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome (HES) [5]
- Discover a COPD Treatment Option | NUCALA (mepolizumab)
NUCALA (mepolizumab) is now approved as an add-on, prescription maintenance treatment for adults with uncontrolled eosinophilic COPD Not for sudden breathing problems
- Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic . . .
Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with
- Mepolizumab (subcutaneous route) - Side effects dosage
Mepolizumab injection is used with other medicines to treat severe asthma It is given to patients whose asthma is not controlled with their current asthma medicines It is also used to treat eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES)
- Mepolizumab Injection: MedlinePlus Drug Information
Mepolizumab injection is used along with other medications to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in certain children 6 years of age and older and adults whose asthma is not controlled with their current asthma medication (s)
- label - Food and Drug Administration
Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma, CRSwNP, EGPA, and HES has not been
- INTRODUCTION - Mepolizumab (Nucala) - NCBI Bookshelf
Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine responsible for regulating eosinophil maturation, differentiation, recruitment, activation, and survival
|